Pharmacokinetics of acyclovir in the cat

Journal of Veterinary Pharmacology and Therapeutics

Volumn 19, Issue 6, 1996, Pages 488-490

  Owens, J G ^a   Nasisse, M P ^b   Tadepalli, S M ^c   Dorman, D C ^d  

^a PFIZER INC   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c GLAXOSMITHKLINE   (United States)

^d CIIT CENTERS FOR HEALTH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; VALACICLOVIR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CAT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; MEAN RESIDENCE TIME; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANIMALIA; FELIS CATUS;

EID: 0030474215     PISSN: 01407783     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2885.1996.tb00087.x     Document Type: Article

References (14)

1. De Miranda, P.E., Krasny, H.C., Page, D.A. & Elion, G.B. (1982) Species differences in the disposition of acyclovir. American Journal of Medicine, 73, 31-35.
2. Elion, G.B. (1982) Mechanisms of action and selectivity of acyclovir. American Journal of Medicine, 73, 7-13.
3. Ellis, T.M. (1981) Feline respiratory virus carriers in clinically healthy cats. Australian Veterinary Journal, 57, 115.
4. Krasny, H.C., De Miranda, P., Blum, M. R. & Elion, G.B. (1981) Pharmacokinetics and bioavailability of acyclovir in the dog. Journal of Pharmacology abd Experimental Therapeutics, 216, 281-288.
5. Gibaldi, M. & Perrier, D. (1982) Noncompartment analysis based on statistical moment theory. In Pharmacokinetics, pp. 409-417. Marcel Dekker, New York.
6. Munger, R.J. & Nasisse, M.P. (1991) Management of chronic ocular disease caused by upper respiratory agents. In: Consultations in Feline Medicine. Ed: August, J.R. pp. 571-576. W.B. Saunders, Philadelphia, PA, USA.
7. Nasisse, M.P., Guy, J. S., Davidson, M.G., Sussman, W. & deClercq, E. (1989) In vitro susceptibility of feline herpesvirus-1 to vidarabine, idoxuridine, trifluridine, acyclovir, or bromovinyldeoxyuridine. American Journal of Veterinary Research, 50, 158-160.
8. Purifoy, D.J.M., Beauchamp, L. M., de Miranda, P. et al. (1993) Review of research leading to new anti-herpesvirus agent in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus. Journal of Medical Virology, Suppl. 1, 139-145.
9. Steel, R. G. D. & Torrie, J. H. (1980) Nonparametric statistics. In: Principles and Procedures of Statistics. Eds: by Napier, C. & Maisel, J.W. pp. 533-553. McGraw-Hill Book Company, New York.
10. Studdert, M.J. & Martin, M.C. (1970) Virus diseases of the respiratory tract of cats: isolation of feline rhinotracheitis virus. Australian Veterinary Journal, 46, 99-104.
11. Tadepalli, S.M. & Quinn, K.P. (1996) Scintillation proximity radioimmunoassay for the measurement of acyclovir. Journal of Pharmaceutical and Biochemical Analysis (in press).
12. Tadepalli S., Topham, P. & Quinn, R.P. (1990) Scintillation proximity radioimmunassay for the measurement of acyclovir. Clinical Chemistry, 36, 1104 (Abstract).
13. Weiss, R.C. (1989) Synergistic antiviral activities of acyclovir and recombinant human leukocyte (alpha) interferon on feline herpesvirus replication. American Journal of Veterinary Research, 50, 1672-1677.
14. Weiler, S., Blum, M.R., Doucette, M. et al. (1993) Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clinical Pharmacology and Therapeutics, 54, 595-605.